Bronchial Spasm Market Size & Share, by Treatment Type {Short-Acting Bronchodilators (Albuterol, Levalbuterol), Long-Acting Bronchodilators (Aclidinium, Salmeterol, Formoterol, Indacaterol), Inhaled & Oral Steroids}; Diagnosis (Arterial Blood Gas Tests, Chest X-Ray, C.T. Scans); Cause (COPD, Asthma, Chronic Bronchitis, Emphysema); End-user (Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4394
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Bronchial Spasm Landscape

    • GSK plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sunovion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Viatris Inc.
    • Pfizer Inc.
    • The Bristol-Myers Squibb Company 
    • Sanofi S.A
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca plc
    • Novartis AG

Browse Key Market Insights with Data Illustration:


In The News

  • GSK plc to acquire the acceptance for its new drug application from US Food and Drug Administration (FDA). This new drug application (NDA) has been developed for the treatment of myelofibrosis patients with anemia.

  • Sunovion Pharmaceuticals Inc. to provide support for the Next Generation of Innovators with the Red Sox Foundation. The program is entirely on assisting the scholars who are exploring STEM and life sciences. Furthermore, the program is also becoming advantageous for students to receive better mentoring and coaching. 

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4394
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of fungal infection and rising cases of COPD across the globe are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2033.

Shortage of medication and skilled medical professionals is estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Sunovion Pharmaceuticals Inc., Merck & Co., Inc., Viatris Inc., Pfizer Inc., The Bristol-Myers Squibb Company, Sanofi S.A, Teva Pharmaceutical Industries Ltd. and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, diagnosis, cause, end-user, and region.

The short-acting bronchodilators segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying